- Contract covers Light Path™ Discovery Custom Material Supply for pre-clinical testing
- Protein production will be conducted at Lonza’s Mammalian facility in Cambridge, UK
- Since the launch of Light Path™ in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing
Basel (Switzerland), 07 March 2012 – Lonza announced today an agreement with Korean Biotech, LegoChem Biosciences, for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Under this agreement, Lonza will produce pre-clinical material using Light Path™ Discovery Services at its applied protein services facility in Cambridge, UK.
“Lonza’s Light Path™ Discovery Services were specifically designed with the demands of pre-clinical assessment in mind,” said Janet White, Head of Lonza’s Development Services. “Lonza has built a strong reputation for CMO excellence. Today, we’re also focusing efforts on supporting emerging biotechnology innovation at every stage of development to allow each customer the best chance for clinical success.”
Woo, Sung Ho, Ph.D., Biology Director/Senior Vice President of LegoChem Biosciences said, “We have chosen to work with Lonza on this important project because of their reliability and solid reputation in field of mammalian development.”
Lonza’s Light Path™ Custom Material Services supports projects in their early phase, providing cGMP product within 11 months. In addition, Lonza’s Light Path™ Discovery Service provides non-GMP product in 6 to 10 weeks, to support customers in the discovery testing phase. Since the launch of Light Path™ in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing. Light Path™ allows customers to reach their clinical milestones more efficiently.